-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Pharmaceutical Guanlan
On November 10, the Center for Drug Evaluation (CDE) of the National Food and Drug Administration of China announced that the Class 1 new drug GH21 capsules declared by Qin Hao Medicine had obtained the implied license for clinical trials and planned to be developed for advanced solid tumors
Screenshot source: CDE official website
The full name of SHP2 is a protein tyrosine phosphatase containing Src homology 2 domain
According to Qinhao Pharmaceutical’s earlier press release, GH21 is a small molecule anti-tumor drug with great potential for development.
In September 2020, Qinhao Pharmaceutical and Huya Bio-International reached an exclusive license agreement, granting the latter the right to develop and commercialize GH21 products outside of China
Reference materials:
[1] Drug Evaluation Center of China National Medical Products Administration.